Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-20T14:39:58.146Z Has data issue: false hasContentIssue false

Effect of n-3 PUFA on left ventricular remodelling in chronic heart failure: a systematic review and meta-analysis

Published online by Cambridge University Press:  04 March 2022

Jing Liu
Affiliation:
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Department of Burn & Plastic Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, People’s Republic of China
Qingshu Meng
Affiliation:
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Institute of Integrated Traditional Chinese and Western Medicine for Cardiovascular Chronic Diseases, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Shanghai Heart Failure Research Center, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China
Liang Zheng
Affiliation:
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Institute of Integrated Traditional Chinese and Western Medicine for Cardiovascular Chronic Diseases, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Shanghai Heart Failure Research Center, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China
Ping Yu
Affiliation:
Department of Heart Failure, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China
Hao Hu
Affiliation:
Department of Heart Failure, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China
Rulin Zhuang
Affiliation:
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Department of Cardiovascular Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China
Xinyu Ge
Affiliation:
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Department of Cardiovascular Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China
Zhongmin Liu
Affiliation:
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Shanghai Heart Failure Research Center, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Department of Cardiovascular Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China
Xiaoting Liang*
Affiliation:
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Institute of Integrated Traditional Chinese and Western Medicine for Cardiovascular Chronic Diseases, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Shanghai Heart Failure Research Center, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200120, People’s Republic of China
Xiaohui Zhou*
Affiliation:
Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Institute of Integrated Traditional Chinese and Western Medicine for Cardiovascular Chronic Diseases, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China Shanghai Heart Failure Research Center, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People’s Republic of China
*
*Corresponding authors: Xiaoting Liang, email liangxt@tongji.edu.cn; Xiaohui Zhou, email zxh100@tongji.edu.cn
*Corresponding authors: Xiaoting Liang, email liangxt@tongji.edu.cn; Xiaohui Zhou, email zxh100@tongji.edu.cn

Abstract

Accumulating evidence suggests that supplementation of n-3 PUFA was associated with reduction in risk of major cardiovascular events. This meta-analysis was to systematically evaluate whether daily supplementation and accumulated intake of n-3 PUFA are associated with improved left ventricular (LV) remodelling in patients with chronic heart failure (CHF). Articles were obtained from Pubmed, Clinical key and Web of Science from inception to January 1 in 2021, and a total of twelve trials involving 2162 participants were eligible for inclusion. The sources of study heterogeneity were explained by I2 statistic and subgroup analysis. Compared with placebo groups, n-3 PUFA supplementation improved LV ejection fraction (LVEF) (eleven trials, 2112 participants, weighted mean difference (WMD) = 2·52, 95 % CI 1·25, 3·80, I2 = 87·8 %) and decreased LV end systolic volume (five studies, 905 participants, WMD = –3·22, 95 % CI 3·67, −2·77, I2 = 0·0 %) using the continuous variables analysis. Notably, the high accumulated n-3 PUFA dosage groups (≥ 600 g) presented a prominent improvement in LVEF, while the low and middle accumulated dosage (≤ 300 and 300–600 g) showed no effects on LVEF. In addition, n-3 PUFA supplementation decreased the levels of pro-inflammatory mediators including TNF-α, IL-6 (IL-6) and hypersensitive c-reactive protein. Therefore, the present meta-analysis demonstrated that n-3 PUFA consumption was associated with a substantial improvement of LV function and remodelling in patients subjected to CHF. The accumulated dosage of n-3 PUFA intake is vital for its cardiac protective role.

Type
Systematic Review and Meta-Analysis
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Nutrition Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bhatt, AS, Ambrosy, AP & Velazquez, EJ (2017) Adverse remodeling and reverse remodeling after myocardial infarction. Curr Cardiol Rep 19, 71.CrossRefGoogle ScholarPubMed
Yancy, CW, Jessup, M, Bozkurt, B, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62, e147e239.CrossRefGoogle Scholar
Shirazi, LF, Bissett, J, Romeo, F, et al. (2017) Role of inflammation in heart failure. Curr Atheroscler Rep 19, 27.CrossRefGoogle Scholar
Moertl, D, Hammer, A, Steiner, S, et al. (2011) Dose-dependent effects of n-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 161, e911919.CrossRefGoogle Scholar
Van Tassell, BW, Seropian, IM, Toldo, S, et al. (2013) Interleukin-1beta induces a reversible cardiomyopathy in the mouse. Inflamm Res 62, 637640.CrossRefGoogle ScholarPubMed
Ziaeian, B & Fonarow, GC (2016) Epidemiology and aetiology of heart failure. Nat Rev Cardiol 13, 368378.CrossRefGoogle ScholarPubMed
Kris-Etherton, PM, Harris, WS, Appel, LJ, et al. (2003) n-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 23, 151152.CrossRefGoogle ScholarPubMed
National Heart Foundation of A & Cardiac Society of A and New Z. (2001) Lipid management guidelines – 2001. National Heart Foundation of Australia, The Cardiac Society of Australia and New Zealand. Med J Aust 175, S6285.Google Scholar
Krauss, RM, Eckel, RH, Howard, B, et al. (2000) AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102, 22842299.CrossRefGoogle ScholarPubMed
Mozaffarian, D, Bryson, CL, Lemaitre, RN, et al. (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45, 20152021.CrossRefGoogle ScholarPubMed
Yamagishi, K, Iso, H, Date, C, et al. (2008) Fish, n-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese Men and Women: the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol 52, 988996.CrossRefGoogle Scholar
Van Linthout, S & Tschöpe, C (2017) Inflammation-cause or consequence of heart failure or both? Curr Heart Fail Rep 14, 251265.CrossRefGoogle ScholarPubMed
Tavazzi, L, Maggioni, AP, Marchioli, R, et al. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 12231230.Google Scholar
Ghio, S, Scelsi, L, Latini, R, et al. (2010) Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 12, 13451353.CrossRefGoogle ScholarPubMed
Xin, W, Wei, W & Li, X (2012) Effects of fish oil supplementation on cardiac function in chronic heart failure: a meta-analysis of randomised controlled trials. Heart 98, 16201625.CrossRefGoogle ScholarPubMed
Heydari, B, Abdullah, S, Pottala, JV, et al. (2016) Effect of n-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial. Circulation 134, 378391.CrossRefGoogle Scholar
Risk and Prevention Study Collaborative Group, Roncaglioni, MC, Massimo, T, et al. (2013) n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 368, 18001808.Google ScholarPubMed
Bernhard Rauch, B, Schiele, R, Schneider, S, et al. (2010) omega, a randomized, placebo-controlled trial to test the effect of highly purified n-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122, 21522159.CrossRefGoogle Scholar
Kromhout, D, Giltay, EJ & Geleijnse, JM (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363, 20152026.CrossRefGoogle ScholarPubMed
Dijkstra, SC, Brouwer, IA, van Rooij, FJ, et al. (2009) Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail 11, 922928.CrossRefGoogle ScholarPubMed
Moher, D, Cook, DJ, Eastwood, S, et al. (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354, 18961900.CrossRefGoogle ScholarPubMed
Hozo, SP, Djulbegovic, B & Hozo, I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5, 13.CrossRefGoogle ScholarPubMed
Higgins, JP, Thompson, SG, Deeks, JJ, et al. (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557560.CrossRefGoogle ScholarPubMed
Chrysohoou, C, Metallinos, G, Georgiopoulos, G, et al. (2016) Short term n-3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; a randomized clinical trial. Vascul Pharmacol 79, 4350.CrossRefGoogle ScholarPubMed
Skou, HA, Toft, E, Christensen, JH, et al. (2001) n-3 fatty acids and cardiac function after myocardial infarction in Denmark. Int J Circumpolar Health 60, 360365.CrossRefGoogle ScholarPubMed
Radaelli, A, Cazzaniga, M, Viola, A, et al. (2006) Enhanced baroreceptor control of the cardiovascular system by polyunsaturated Fatty acids in heart failure patients. J Am Coll Cardiol 48, 16001606.CrossRefGoogle ScholarPubMed
Zhao, YT, Shao, L, Teng, LL, et al. (2009) Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res 37, 18311841.CrossRefGoogle Scholar
Nodari, S, Metra, M, Milesi, G, et al. (2009) The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther 23, 515.CrossRefGoogle ScholarPubMed
Nodari, S, Triggiani, M, Campia, U, et al. (2011) Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 57, 870879.CrossRefGoogle ScholarPubMed
Kojuri, J, Ostovan, MA, Rezaian, GR, et al. (2013) Effect of n-3 on brain natriuretic peptide and echocardiographic findings in heart failure: double-blind placebo-controlled randomized trial. J Cardiovasc Dis Res 4, 2024.CrossRefGoogle Scholar
Kohashi, K, Nakagomi, A, Saiki, Y, et al. (2014) Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. J Atheroscler Thromb 21, 712729.CrossRefGoogle ScholarPubMed
Campos-Staffico, AM, Costa, APR, Carvalho, LSF, et al. (2019) n-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction. Nutr J 18, 29.CrossRefGoogle Scholar
Joint FA & Consultation WE (2009) Fats and Fatty Acids in Human Nutrition. Geneva: Joint FA.Google Scholar
Hamzic-Mehmedbasic, A (2016) Inflammatory cytokines as risk factors for mortality after acute cardiac events. Med Arch 70, 252255.CrossRefGoogle ScholarPubMed
Farnsworth, CW, Bailey, AL, Jaffe, AS, et al. (2018) Diagnostic concordance between NT-proBNP and BNP for suspected heart failure. Clin Biochem 59, 5055.CrossRefGoogle ScholarPubMed
Siscovick, DS, Barringer, TA, Fretts, AM, et al. (2017) n-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 135, e867e884.CrossRefGoogle ScholarPubMed
Aimo, A, Gaggin, HK, Barison, A, et al. (2019) Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart fail 7, 782794.CrossRefGoogle ScholarPubMed
Bhat, PK, Ashwath, ML, Rosenbaum, DS, et al. (2012) Usefulness of left ventricular end-systolic dimension by echocardiography to predict reverse remodeling in patients with newly diagnosed severe left ventricular systolic dysfunction. Am J Cardiol 110, 8387.CrossRefGoogle ScholarPubMed
Barison, A, Grigoratos, C, Todiere, G, et al. (2015) Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance. Heart Fail Rev 20, 731749.CrossRefGoogle ScholarPubMed
De Caterina, R (2011) n-3 fatty acids in cardiovascular disease. N Engl J Med 364, 24392450.CrossRefGoogle ScholarPubMed
Pepe, S & Mclennan, PL (2007) (n-3) long chain PUFA dose-dependently increase oxygen utilization efficiency and inhibit arrhythmias after saturated fat feeding in rats. J Nutr 137, 23772383.CrossRefGoogle ScholarPubMed
Swann, PG, Venton, DL & Breton, G (1989) Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A2/prostaglandin H2 receptor in human platelets. FEBS Lett 243, 244246.CrossRefGoogle ScholarPubMed
Sakamoto, A, Saotome, M, Iguchi, K, et al. (2019) Marine-derived n-3 polyunsaturated fatty acids and heart failure: current understanding for basic to clinical relevance. Int J Mol Sci 20, 4025.CrossRefGoogle ScholarPubMed
Duda, MK, O’Shea, KM, Tintinu, A, et al. (2009) Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 81, 319327.CrossRefGoogle Scholar
Chen, J, Shearer, GC, Chen, Q, et al. (2011) n-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 123, 584593.CrossRefGoogle ScholarPubMed
Wang, C, Xiong, B & Huang, J (2016) The role of n-3 polyunsaturated fatty acids in heart failure: a meta-analysis of randomised controlled trials. Nutrients 9, 18.CrossRefGoogle Scholar
Huang, T, Wang, T, Heianza, Y, et al. (2019) Habitual consumption of long-chain n-3 PUFAs and fish attenuates genetically associated long-term weight gain. Am J Clin Nutr 109, 665673.CrossRefGoogle ScholarPubMed
Lahoz, C, Castillo, E, Mostaza, JM, et al. (2018) Relationship of the adherence to a Mediterranean diet and its main components with CRP levels in the Spanish Population. Nutrients 10, 379.CrossRefGoogle ScholarPubMed
Nelson, JR, True, WS, Le, V, et al. (2017) Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Postgrad Med 129, 822827.CrossRefGoogle ScholarPubMed
Skulas-Ray, AC, Wilson, PW, Harris, WS, et al. (2019) n-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American heart association. Circulation 140, e673e691.CrossRefGoogle ScholarPubMed
Mach, F, Baigent, C, Catapano, AL, et al. (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41, 111188.CrossRefGoogle ScholarPubMed
Nicholls, SJ, Lincoff, AM, Garcia, M, et al. (2020) Effect of high-dose n-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 324, 22682280.CrossRefGoogle ScholarPubMed
Bhatt, DL, Steg, PG, Miller, M, et al. (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380, 1122.CrossRefGoogle ScholarPubMed
Jo, SH, Han, SH, Kim, SH, et al. (2021) Cardiovascular effects of n-3 fatty acids: hope or hype? Atherosclerosis 322, 1523.CrossRefGoogle ScholarPubMed
Sharma, G, Martin, SS & Blumenthal, RS (2020) Effects of n-3 fatty acids on major adverse cardiovascular events what matters most: the drug, the dose, or the placebo? JAMA 324, 22622264.CrossRefGoogle ScholarPubMed
White, HD, Norris, RM, Brown, MA, et al. (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76, 4451.CrossRefGoogle ScholarPubMed
Mishra, A, Srivastava, A, Mittal, T, et al. (2013) Role of inflammatory gene polymorphisms in left ventricular dysfunction (LVD) susceptibility in coronary artery disease (CAD) patients. Cytokine 61, 856861.CrossRefGoogle ScholarPubMed
Aukrust, P, Yndestad, A, Waehre, T, et al. (2005) Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Rev Cardiovasc Ther 3, 11111124.CrossRefGoogle ScholarPubMed
Li, X, Chen, C, Gan, F, et al. (2014) Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovasc Disord 14, 67.CrossRefGoogle ScholarPubMed
Mehra, MR, Lavie, CJ, Ventura, HO, et al. (2006) Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant 25, 834838.CrossRefGoogle ScholarPubMed
Duda, MK, O’Shea, KM & Stanley, WC (2009) n-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovas Res 84, 3341.CrossRefGoogle ScholarPubMed
Ono, K, Matsumori, A, Shioi, T, et al. (1998) Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98, 149156.CrossRefGoogle ScholarPubMed
Supplementary material: Image

Liu et al. supplementary material

Liu et al. supplementary material 1

Download Liu et al. supplementary material(Image)
Image 189.7 KB
Supplementary material: File

Liu et al. supplementary material

Liu et al. supplementary material 2

Download Liu et al. supplementary material(File)
File 42.1 KB